Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Dyslipidemia

Free Subscription Articles published in Circulation Retrieve available abstracts of 19 articles: HTML format

Single Articles

January 2026
1. FEARON WF, Terada K, Takahashi K, Skoda A, et al
   Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial.
   Circulation. 2026;153:7-17.
   PubMed     Abstract available
   
   
   August 2025
2. LIU Y, Wang H, Yu M, Cai L, et al
   Hypertriglyceridemia as a Key Contributor to Abdominal Aortic Aneurysm Development and Rupture: Insights From Genetic and Experimental Models.
   Circulation. 2025 Aug 5:10.1161/CIRCULATIONAHA.125.074737.
   PubMed     Abstract available
   
   
   May 2025
3. WIEGMAN A, Peterson AL, Hegele RA, Bruckert E, et al
   Efficacy and Safety of Inclisiran in Adolescents With Genetically Confirmed Homozygous Familial Hypercholesterolemia: Results From the Double-Blind, Placebo-Controlled Part of the ORION-13 Randomized Trial.
   Circulation. 2025 May 20. doi: 10.1161/CIRCULATIONAHA.124.073233.
   PubMed     Abstract available
   
   
   January 2025
4. CHEW NWS, Mehta A, Goh RSJ, Zhang A, et al
   Cardiovascular-Liver-Metabolic Health: Recommendations in Screening, Diagnosis, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Cardiovascular Disease via Modified Delphi Approach.
   Circulation. 2025;151:98-119.
   PubMed     Abstract available
   
   
   August 2024
5. DAMASE TR, Sukhovershin R, Godin B, Nasir K, et al
   Established and Emerging Nucleic Acid Therapies for Familial Hypercholesterolemia.
   Circulation. 2024;150:724-735.
   PubMed     Abstract available
   
   
   April 2024
6. TAMARGO IA, Baek KI, Xu C, Kang DW, et al
   HEG1 Protects Against Atherosclerosis by Regulating Stable Flow-Induced KLF2/4 Expression in Endothelial Cells.
   Circulation. 2024;149:1183-1201.
   PubMed     Abstract available
   
   
   February 2024
7. STONE NJ, Blum C
   If Action is Delayed, Is Survival Denied? Management of Severe Hypercholesterolemia Is Important and Urgent.
   Circulation. 2024;149:427-429.
   PubMed    
   
   
   January 2024
8. SANTOS RD, Cuchel M
   LDL-C-Lowering Therapies for Adults and Children With Homozygous Familial Hypercholesterolemia: Challenges and Successes.
   Circulation. 2024;149:363-366.
   PubMed    
   
   
   November 2023
9. YALCINKAYA M, Liu W, Thomas LA, Olszewska M, et al
   BRCC3-Mediated NLRP3 Deubiquitylation Promotes Inflammasome Activation and Atherosclerosis in Tet2 Clonal Hematopoiesis.
   Circulation. 2023;148:1764-1777.
   PubMed     Abstract available
   
   
   
10. MILES J, Scotti A, Castagna F, Kuno T, et al
    Long-Term Mortality in Patients With Severe Hypercholesterolemia Phenotype From a Racial and Ethnically Diverse US Cohort.
    Circulation. 2023 Nov 16. doi: 10.1161/CIRCULATIONAHA.123.064566.
    PubMed     Abstract available
    
    
    October 2023
11. WIEGMAN A, Greber-Platzer S, Ali S, Doortje Reijman M, et al
    Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia.
    Circulation. 2023 Oct 20. doi: 10.1161/CIRCULATIONAHA.123.065529.
    PubMed     Abstract available
    
    
    
12. RAAL F, Durst R, Bi R, Talloczy Z, et al
    Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial.
    Circulation. 2023 Oct 18. doi: 10.1161/CIRCULATIONAHA.122.063460.
    PubMed     Abstract available
    
    
    September 2023
13. ALDANA-BITAR J, Karlsberg RP, Budoff MJ
    Letter by Aldana-Bitar et al Regarding Article, "Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia: The ARCHITECT Study".
    Circulation. 2023;148:1057.
    PubMed    
    
    
    
14. PEREZ DE ISLA L, Saltijeral Cerezo A, Mata P
    Response by Perez de Isla et al to Letter Regarding Article, "Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia: The ARCHITECT Study".
    Circulation. 2023;148:1059-1060.
    PubMed    
    
    
    
15. LONG X, Jiang M
    Letter by Long and Jiang Regarding Article, "Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia: The ARCHITECT Study".
    Circulation. 2023;148:1058.
    PubMed    
    
    
    July 2023
16. LAGU T, Schroth SL, Haywood C, Heinemann A, et al
    Diagnosis and Management of Cardiovascular Risk in Individuals With Spinal Cord Injury: A Narrative Review.
    Circulation. 2023;148:268-277.
    PubMed     Abstract available
    
    
    
17. JOHNS DG, Campeau LC, Banka P, Bautmans A, et al
    Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor.
    Circulation. 2023;148:144-158.
    PubMed     Abstract available
    
    
    May 2023
18. ZHANG Y, Dron JS, Bellows BK, Khera AV, et al
    Association of Severe Hypercholesterolemia and Familial Hypercholesterolemia Genotype With Risk of Coronary Heart Disease.
    Circulation. 2023;147:1556-1559.
    PubMed    
    
    
    April 2023
19. PEREZ DE ISLA L, Diaz-Diaz JL, Romero MJ, Muniz-Grijalvo O, et al
    Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study.
    Circulation. 2023 Apr 3. doi: 10.1161/CIRCULATIONAHA.122.062557.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Dyslipidemia is free of charge.